Use of drug challenge in a case of possible deferoxamine allergy
- 1 May 2020
- journal article
- letter
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (5) , 1737-1739
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Relationship Between Anaphylaxis and Use of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors: A Systematic Review and Meta-Analysis of Observational StudiesThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Drug Allergy: An Updated Practice ParameterAnnals of Allergy, Asthma & Immunology, 2010
- EVALUATION AND MANAGEMENT OF PEDIATRIC PATIENTS WITH ANAPHYLACTOID REACTIONS TO DEFEROXAMINE MESYLATEAnnals of Allergy, Asthma & Immunology, 2007
- Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerationsAllergy, 2003
- Iron-Chelating Therapy and the Treatment of ThalassemiaBlood, 1997
- Continuous low-dose subcutaneous desferrioxamine (DFO) to prevent allergic manifestations in patients with iron overloadAnnals of Hematology, 1996
- High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administrationAmerican Journal of Hematology, 1996
- Desferal (desferrioxamine)—A novel activator of connective tissue-type mast cellsJournal of Allergy and Clinical Immunology, 1991